Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

Medical research article - not related to Iran

Just now November 19, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

This is a medical research article about hepatocellular carcinoma (HCC) treatment and biomarkers, not an article about Iran or Iranian affairs. The article discusses global liver cancer statistics and therapeutic approaches to unresectable HCC.

Liver cancer was the sixth most common cancer and the third leading cause of cancer-related deaths worldwide in 2022, with hepatocellular carcinoma (HCC) as the most common histological subtype, accounting for approximately 90% of liver cancers. Despite this, biomarkers that predict survival and therapeutic response to atezolizumab plus bevacizumab (Atezo/Bev), a type of systemic therapy in HCC management, have yet to be established in unresectable HCC, in which the tumor cannot be safely treated via surgical removal.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →